Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XAV939 |
Trade Name | |
Synonyms | XAV-939 |
Drug Descriptions |
XAV939 selectively inhibits Wnt/beta-catenin-mediated signaling by inhibiting tankyrase1/2, thus stabilizing axin and stimulating beta-catenin degradation (PMID: 19759537, PMID: 32681294). |
DrugClasses | Tankyrase Inhibitor 11 |
CAS Registry Number | 284028-89-3 |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Everolimus + XAV939 | Everolimus XAV939 | 0 | 0 |
Imatinib + XAV939 | Imatinib XAV939 | 1 | 0 |
Palbociclib + XAV939 | Palbociclib XAV939 | 0 | 0 |
unspecified PD-1 antibody + XAV939 | XAV939 unspecified PD-1 antibody | 0 | 0 |
Vandetanib + XAV939 | Vandetanib XAV939 | 0 | 0 |
XAV939 | XAV939 | 8 | 0 |